Published in Therap Adv Gastroenterol on March 01, 2010
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat (2012) 1.38
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One (2014) 1.00
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother (2015) 0.91
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res (2014) 0.85
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Clin Mol Hepatol (2014) 0.83
Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. Int Med Case Rep J (2013) 0.75
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clin Mol Hepatol (2016) 0.75
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Hepatitis B virus infection. N Engl J Med (2008) 6.92
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
The natural history of chronic hepatitis B virus infection. Hepatology (2009) 3.08
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 2.66
Acute kidney injury in cirrhosis. Hepatology (2008) 2.43
Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis (2002) 2.41
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis (2003) 2.21
Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov (2005) 2.14
Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr (2004) 2.12
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med (2003) 1.98
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother (2004) 1.90
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis (2005) 1.87
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (2002) 1.82
Tenofovir-associated renal and bone toxicity. HIV Med (2009) 1.82
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med (2005) 1.80
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (2005) 1.80
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry (2003) 1.67
Drug-induced liver disorders: implications for drug development and regulation. Drug Saf (2001) 1.66
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology (2009) 1.57
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS (2008) 1.57
The significance of mitochondrial toxicity testing in drug development. Drug Discov Today (2007) 1.56
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther (2008) 1.56
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Renal safety of tenofovir in HIV treatment-experienced patients. AIDS (2004) 1.50
Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest (2009) 1.43
Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res (2004) 1.40
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis (2004) 1.37
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci (2002) 1.37
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. J Antimicrob Chemother (2008) 1.29
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther (2008) 1.29
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses (2009) 1.28
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology (2006) 1.28
Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther (2007) 1.26
Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr (2009) 1.21
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med (2009) 1.20
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol (2004) 1.18
Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS (2003) 1.16
Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther (2005) 1.16
The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today (2009) 1.16
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother (2006) 1.14
Epidemiology of hepatitis virus B and C. Arch Med Res (2007) 1.12
Epidemiology of hepatitis B in Canada. Can J Infect Dis (2001) 1.06
Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res (2003) 1.06
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother (2005) 1.06
Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol (2009) 1.06
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet (2006) 1.05
Endpoints of therapy in chronic hepatitis B. Hepatology (2009) 1.01
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology (2003) 1.00
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat (2007) 0.96
Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat (2008) 0.96
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS (2003) 0.95
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.93
Tenofovir-induced kidney injury. Expert Opin Drug Saf (2007) 0.92
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity. J Biol Chem (2007) 0.90
Is phosphatemia the best tool to monitor renal tenofovir toxicity? J Acquir Immune Defic Syndr (2007) 0.87
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther (2008) 0.86
[Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir]. Rev Esp Med Nucl (2006) 0.85
The birth of a new radiopharmaceutical. Industrial perspective: from IND to NDA. J Nucl Cardiol (1998) 0.83
Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients. Ther Clin Risk Manag (2008) 0.79
Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Ther (2009) 0.78
HIV and the kidney: a status report after 20 years. Curr HIV/AIDS Rep (2004) 0.76
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Primary biliary cirrhosis. Hepatology (2009) 5.35
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology (2005) 1.89
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol (2008) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol (2005) 1.58
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology (2005) 1.49
Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology (2010) 1.47
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology (2008) 1.46
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology (2004) 1.42
Sclerosing cholangitis: a focus on secondary causes. Hepatology (2006) 1.37
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Primary biliary cirrhosis. Orphanet J Rare Dis (2008) 1.31
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology (2013) 1.26
Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey. Can J Gastroenterol (2011) 1.19
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol (2006) 1.16
Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 1.16
Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol (2010) 1.14
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun (2010) 1.13
Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10
Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut (2010) 1.08
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2007) 1.03
Endpoints of therapy in chronic hepatitis B. Hepatology (2009) 1.01
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol (2010) 0.97
High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol (2003) 0.97
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2012) 0.96
CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. Arthritis Rheum (2009) 0.92
Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci (2006) 0.91
Pediatric-onset primary biliary cirrhosis. Gastroenterology (2003) 0.90
Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology (2008) 0.90
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol (2006) 0.88
Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr (2009) 0.88
Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology (2008) 0.88
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther (2012) 0.88
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol (2002) 0.87
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). Br J Clin Pharmacol (2009) 0.87
Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol (2009) 0.86
Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis (2006) 0.86
Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver (2002) 0.86
Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol (2008) 0.84
Preventative hepatology: minimising symptoms and optimising care. Liver Int (2008) 0.84
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83
Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol (2009) 0.83
Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int (2010) 0.82
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol (2007) 0.82
Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology (2010) 0.82
Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int (2011) 0.82
Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J Hepatol (2008) 0.82
Impact of a formal mentoring program on academic promotion of Department of Medicine faculty: a comparative study. Med Teach (2014) 0.82
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int (2015) 0.81
Impact of cirrhosis and liver transplant on maternal health during labor and delivery. Clin Gastroenterol Hepatol (2009) 0.81
A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology (2005) 0.81
Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol (2008) 0.81
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol (2013) 0.81
Benefit of transplantation in primary biliary cirrhosis between 1985-1997. Transplantation (2002) 0.79
Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition. Curr HIV Res (2011) 0.78
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. J Hepatol (2010) 0.78
Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci (2006) 0.78
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am J Gastroenterol (2009) 0.76
Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci (2007) 0.76
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res (2006) 0.76
Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention. J Obes (2011) 0.75
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 0.75
A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful? Am J Hematol (2005) 0.75